NCT01089101
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
At risk: Primary endpoint(s) modified.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 194 versions: 4 with changes below, 46 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria shortened, about 425 words
- Notable Eligibility criteria expanded, about 687 words
- Secondary endpoints: 4 to 7
- Study description expanded, about 1 word
- New version filed on ClinicalTrials.gov
- Minor Enrollment target: estimated 220 to confirmed 217
- Primary completion date changed from estimate of Jul 31, 2026 to Jan 17, 2026
- Study completion date: Jul 31, 2026 to Mar 18, 2027
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity. Patients who experience a sustained objective response from selumetinib on the phase I or phase II portions of the trial, and who have completed 2 years of treatment and stopped study drug may be enrolled on the re-treatment study after progression/recurrence. Patients in the re-treatment study may continue treatment indefinitely in the absence of disease progression or unacceptable toxicities. Patients undergo blood sample collection on study.
Procedures: Biospecimen Collection
Drugs: Selumetinib
Sites
17 sites in 1 country